BioMarin to acquire Amicus Therapeutics for $4.8 billion ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Amicus
since
auto-detected in 1 stories
71 days ago
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.
page 1 of 1